Limosilactobacillus vaginalisの機能と安全性プロファイルと,腸内微生物群の調節のための口服用急速分解錠剤の開発
Barbara Giordani1, Federica Monti1, Elisa Corazza1
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, 40127 Bologna, Italy.
Pharmaceutics
|August 28, 2025
まとめ
Limosilactobacillus vaginalis BC17は,生存可能な細胞とポストバイオティクスとして,有益な腸内細菌の粘着を促進し,有害な病原体の粘着を減少させます. 経口製薬は乳児と成人の腸の健康を改善する見込みがある.
科学分野:
- 微生物学
- 胃腸内科
- 栄養学
背景:
- 早期の腸内微生物の植民は 赤ちゃんの健康に不可欠で 経産はビフィドバクテリアを好む
- Limosilactobacillus vaginalis (L. vaginalis) のBC17が腸の健康を支える可能性があることは,調査が必要である.
- L. vaginalis BC17による口服薬の開発は腸の健康にとって重要です.
研究 の 目的:
- L. vaginalis BC17の生存可能な細胞とポストバイオティクスの健康促進特性を評価する.
- L. vaginalis BC17の安全性と有効性を評価する.
- L. vaginalis BC17の安定した経口製剤を開発する.
主な方法:
- 評価された安全性,抗炎症効果,腸内細胞系への微生物粘着への影響.
- L. vaginalis BC17の成分を冷凍乾燥して製成した素早く分解する錠剤です.
- 口服用薬の安定性と機能性を評価した.
主要な成果:
- L. vaginalis BC17の製剤は遺伝子毒性なく,腸内細胞と互換性がありました.
- BC17は有益なビフィドバクテリアの粘着性を250%高め,腸病原菌を40~70%減少させた.
- 安定した配方で3ヶ月間,抗炎症効果が認められた.
結論:
- L. vaginalis BC17の生存可能な細胞とポストバイオティクスは,有望な機能と安全性プロファイルを示しています.
- 素早く分解する錠剤は,L. vaginalis BC17の有効な投与方法である.
- この戦略は 腸の健康を促進するための 説得力のあるアプローチであり, in vivoでの検証を待っています
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
260
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
260
Surface Membrane Barriers
1.5K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.5K
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
303
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
303
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
201
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
201
Drugs Affecting GI Tract Motility: Other Laxatives
447
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
447


